CA2837758A1 - Panels de polymorphismes predictifs de la cardiotoxicite induite par l'anthracycline (act) - Google Patents

Panels de polymorphismes predictifs de la cardiotoxicite induite par l'anthracycline (act) Download PDF

Info

Publication number
CA2837758A1
CA2837758A1 CA2837758A CA2837758A CA2837758A1 CA 2837758 A1 CA2837758 A1 CA 2837758A1 CA 2837758 A CA2837758 A CA 2837758A CA 2837758 A CA2837758 A CA 2837758A CA 2837758 A1 CA2837758 A1 CA 2837758A1
Authority
CA
Canada
Prior art keywords
nucleic acid
seq
acid molecule
oligonucleotide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837758A
Other languages
English (en)
Inventor
Michael R. Hayden
Bruce Carleton
Colin Ross
Hendrik Visscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CA2837758A1 publication Critical patent/CA2837758A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
CA2837758A 2011-05-31 2012-05-31 Panels de polymorphismes predictifs de la cardiotoxicite induite par l'anthracycline (act) Abandoned CA2837758A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491408P 2011-05-31 2011-05-31
US61/491,408 2011-05-31
US201161540436P 2011-09-28 2011-09-28
US61/540,436 2011-09-28
PCT/CA2012/000529 WO2012162812A1 (fr) 2011-05-31 2012-05-31 Panels de polymorphismes prédictifs de la cardiotoxicité induite par l'anthracycline (act)

Publications (1)

Publication Number Publication Date
CA2837758A1 true CA2837758A1 (fr) 2012-12-06

Family

ID=47258221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837758A Abandoned CA2837758A1 (fr) 2011-05-31 2012-05-31 Panels de polymorphismes predictifs de la cardiotoxicite induite par l'anthracycline (act)

Country Status (3)

Country Link
AU (1) AU2012262581A1 (fr)
CA (1) CA2837758A1 (fr)
WO (1) WO2012162812A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106987906A (zh) * 2017-05-15 2017-07-28 重庆市肿瘤研究所 肿瘤治疗心脏毒性预测基因突变检测文库的构建方法
CN107179366B (zh) * 2017-06-13 2019-11-05 南京大学 一种沉积物中氯代有机污染物高通量非靶向筛查鉴定方法
CN111378750A (zh) * 2018-12-29 2020-07-07 北京福安华生物科技有限公司 检测SLC28A3基因rs885004位点多态性的人工模拟核酸分子信标与试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312907A1 (en) * 2006-11-15 2011-12-22 Michael Hayden Polymorphisms predictive of anthracycline- induced cardiotoxicity

Also Published As

Publication number Publication date
AU2012262581A1 (en) 2014-01-16
WO2012162812A1 (fr) 2012-12-06

Similar Documents

Publication Publication Date Title
US20060068428A1 (en) Identification of genetic markers associated with parkinson disease
US20090298711A1 (en) Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects
US20130344170A1 (en) Polymorphisms predictive of anthracycline- induced cardiotoxicity
CA2837758A1 (fr) Panels de polymorphismes predictifs de la cardiotoxicite induite par l'anthracycline (act)
US9650678B2 (en) Methods for identifying an increased risk of anthracycline-related cardiotoxicity
US20140023726A1 (en) Polymorphisms predictive of platinum-coordinating complex induced ototoxicity
US20150044239A1 (en) Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms
US20110110930A1 (en) Mitogen-Activated Protein Kinase Kinase Kinase 14 (MAP3K14) Polymorphisms As Indicators of Subject Outcome in Critically Ill Subjects
US20140147516A1 (en) Polymorphisms predictive of platinum-coordinating compound-induced ototoxicity
US20230193388A1 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotranmitter transporters
EP2584039B1 (fr) Snp destiné à prédire la sensibilité à une formulation thérapeutique anticancéreuse ciblée
US20220349008A1 (en) Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same
CA2911709A1 (fr) Polymorphismes de gene gamma recepteur d'acide retinoique predicteurs de cardiotoxicite induite par l'antrhacycline
US20110171200A1 (en) Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
EP2531261B1 (fr) Méthodes diagnostiques et traitement du diabète non insulinodépendant

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170531